Abstract: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The present invention relates to diagnosing Canine Exercise-Induced Collapse (EIC).

Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.

Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Fused pyrimidines of formula (I): wherein A, n, R1, R2, and R3 have any of the values defined herein and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.

Abstract: Fused pyrimidines of formula (I): wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: Various embodiments of the present invention provide systems, methods, and processes for constructing a contact lens. In one embodiment, a contact lens assembly is provided, comprising: a curved polymer polarizer with an aperture; a lenslet disposed inside the aperture, wherein the lenslet enables imaging near objects; and a filter attached to the lenslet. In further embodiments, a method for fabricating a flexible contact lens is provided, comprising: fabricating an element having an extrusion; providing a front concave mold, wherein the front mold has an intrusion to accommodate the extrusion of the optical element; affixing the extrusion of the optical element to the intrusion of the front mold; attaching a back convex mold to the front concave mold, thereby forming a mold cavity; and filling the mold cavity with a pre-polymerized liquid, whereby upon polymerization, the pre-polymerized liquid forms the flexible contact lens and the optical element is partially encapsulated within the lens.

Abstract: The present invention provides streptococcal SspB Adherence Region (BAR) peptides consisting of Formula I: R18-R1- R2-Val-R3-R4-Leu-Leu-R5-R6-R7-Ile-R8-R9-Lys-R10-R19 , wherein R2, is 1-3 Lys residues; R3 is any amino acid residue except a Pro residue; R4 is any amino acid residue except a Pro residue; R5 is 1-3 Lys residues; R6 is 1-10 amino acid residues; R7 is any amino acid residue except Asp, Glu, Gly or Pro; R8 is any amino acid residue except Ala, Asp, Gly, His, Ile, Pro, Trp or Tyr; R9 is a Val, Ile, Phe, or Trp residue; R10 is 0-1 Cys residue; R18 is 0 amino acids or R12-R11-Pro-, wherein R11 is 0-3 amino acids, wherein the amino acid residues are not Gly or Pro; and R12 is 0-1 Cys residues; and R19 is R13-R14-R15-R16-R17, wherein R13 is 0-1 is Gly residue; R14 is 0-1 Ala residue; R15 is 0-1 Phe residue; R16 is 0-1 Gln residue; R17 is 0-1 Cys residue; and wherein R1 is an ornithine residue; or wherein both R1 and R10 are both Cys and R1 and R10 are covalently linked to form a circular peptide; or whe

Abstract: Applicants have produced and isolated chemically cross-linked complexes of endotoxin and modified MD-2, and have developed methods of using these complexes.

Abstract: The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.

Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.

Abstract: The present invention relates to a selection marker system for distinguishing genetically modified plant cells from wild-type plant cells comprising (a) a nucleic acid sequence coding for choline oxidase, choline monooxygenase and/or choline dehydrogenase for genetically modifying at least a part of a plant and; (b) at least a part of a wild-type plant of the same plant species, wherein the part of the plant which is genetically modified by the nucleic acid sequence coding for choline oxidase, choline monooxygenase and/or choline dehydrogenase is capable of surviving in a medium containing choline at a concentration which is toxic to the wild-type plant. Furthermore, the invention relates to a method for screening and/or identifying a choline tolerant plant cell and the use of a nucleic sequence coding for a choline oxidase, choline monooxygenase and/or choline dehydrogenase as a selection marker for choline tolerance.

Abstract: The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells.

Abstract: The invention provides compounds of formula I: wherein A, B, D, E, R1, R2, R3, R4, R5, X, and ----- have any values defined herein, as well as salts thereof. The compounds have activity as G-quadruplex DNA stabilizers and as anti-proliferative agents.

Abstract: Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2.

Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an anti-inflammatory agent. These methods are useful in a variety of dental and orthopedic applications.

Abstract: The invention features compact apparatuses useful in electrosurgery. The compact apparatuses have a housing having a cavity, an electrosurgical system located within the cavity, the electrosurgical system having optionally a monopolar output system, optionally a bipolar output system, optionally an argon plasma coagulation output system, a processor located within the cavity, the processor operatively coupled to each output system of the electrosurgical system to control outputs generated by each output system, optionally a high frequency generator located within the cavity and operatively coupled to the processor; and a gas canister holder and control system located within the cavity of the housing for receiving a gas canister within the cavity of the housing.

Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.